Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial

Jason Gotlib, MD, Hanneke C. Kluin-Nelemans, MD, PhD, Tracy I. George, MD, Cem Akin, MD, PhD, Karl Sotlar, MD, Olivier Hermine, Farrukh Awan, MD, MS, Elizabeth Hexner, MD, Michael Mauro, MD, Rodica Morariu, MD, Margaret Squier, MD, PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, John Coombs, PharmD, MBA, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2013) 122 (21): 106.

https://doi.org/10.1182/blood.V122.21.106.106

Published: 2013

Journal Articles

Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles.

Jennifer L Beaumont, MS, Matthew Magestro, John Coombs, PharmD, MBA, Xiaolin Fan, PhD, Charisse Kemp, Roger J. Waltzman, MD

Blood (2012) 120 (21): 3166.

https://doi.org/10.1182/blood.V120.21.3166.3166

Published: 2012

Journal Articles

Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?

Jennifer L Beaumont, MS, Cindy Nowinski, MD PhD, John Coombs, PharmD, MBA, Tomasz Szczudlo, Rick E. Blakesley, PhD, Neil J. Gallagher, MD, PhD, James Burns, MS, David Cella, PhD

Blood (2011) 118 (21): 1025.

https://doi.org/10.1182/blood.V118.21.1025.1025

Published: 2011

Journal Articles

Number Needed to Treat (NNT) and Cost Estimation to Achieve a Major Molecular Response in Newly Diagnosed Chronic-phase cronic Myeloid Leukemia in Brasil: 24-months follow-up

Marcia Dias Alves, MBA, John Coombs, PharmD, MBA, Jefferson Ruiz, MD, Joice Valentim, PhD, Marta M. Lemos, MD

Blood (2011) 118 (21): 4216.

https://doi.org/10.1182/blood.V118.21.4216.4216

Published: 2011

Journal Articles

Burden of Illness of Aggressive Systemic Mastocytosis (ASM)

Michelle L Sotak, MPH, MBA, Mihaela Marin, MD, MSc, John Coombs, PharmD, MBA, April Teitelbaum, MD, MS

Blood (2011) 118 (21): 4755.

https://doi.org/10.1182/blood.V118.21.4755.4755

Published: 2011

Journal Articles

Burden of Illness of FLT-3 Mutated Acute Myeloid Leukemia (AML)

Michelle L Sotak, MPH, MBA, Mihaela Marin, MD, MSc, John Coombs, PharmD, MBA, Gary J. Schiller, MD, April Teitelbaum, MD, MS

Blood (2011) 118 (21): 4765.

https://doi.org/10.1182/blood.V118.21.4765.4765

Published: 2011

Journal Articles

An Ethnographic Investigation Tracking the Experience of Chronic Myeloid Leukemia (CML) Patients on Tyrosine Kinase Inhibitor (TKI) Therapies

François Guilhot, MD, John Coombs, PharmD, MBA, Tomasz Szczudlo, Oleg Zernovak, MD, Nancy J. Macdonald, PhD, Ari Shapiro, PhD

Blood (2010) 116 (21): 394.

https://doi.org/10.1182/blood.V116.21.394.394

Published: 2010

Journal Articles

Hospitalizations of Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib: Results From a Randomized Phase III Trial

Jennifer L Beaumont, MS*, John Coombs, PharmD, MBA*, amsi Bollu, V, PhD, MBA*, Richard C. Woodman, MD, David Cella, PhD*

Blood (2010) 116 (21): 3826.

https://doi.org/10.1182/blood.V116.21.3826.3826

Published: 2010

Journal Articles

A Global Retrospective and Physician-Based Analysis of Adherence to Tyrosine Kinase Inhibitor (TKI) Therapies for Chronic Myeloid Leukemia (CML).

François Guilhot, MD, John Coombs, PharmD, MBA, Oleg Zernovak, MD, Tomasz Szczudlo, Gianantonio Rosti

Blood (2010) 116 (21): 1514.

https://doi.org/10.1182/blood.V116.21.1514.1514

Published: 2010

Journal Articles

Number Needed to Treat (NNT) and Cost Estimation to Achieve a Major Molecular Response In Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia In Brazil

Marcia Dias Alves, MBA, John Coombs, PharmD, MBA, Jefferson Ruiz, MD, Joice Valentim, PhD, Marta M. Lemos, MD

Blood (2010) 116 (21): 1520.

https://doi.org/10.1182/blood.V116.21.1520.1520

Published: 2010

Journal Articles

Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia.

Meaghan StCharles, PhD, Vamsi K Bollu, PhD, MBA, Elizabeth Hornyak, BA, John Coombs, PharmD, MBA, Christopher M Blanchette, PhD, Daniel J. DeAngelo, MD, PhD

Blood (2009) 114 (22): 2209.

https://doi.org/10.1182/blood.V114.22.2209.2209

Published: 2009

NARROW

Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial

Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles.

Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?

Number Needed to Treat (NNT) and Cost Estimation to Achieve a Major Molecular Response in Newly Diagnosed Chronic-phase cronic Myeloid Leukemia in Brasil: 24-months follow-up

Burden of Illness of Aggressive Systemic Mastocytosis (ASM)

Burden of Illness of FLT-3 Mutated Acute Myeloid Leukemia (AML)

An Ethnographic Investigation Tracking the Experience of Chronic Myeloid Leukemia (CML) Patients on Tyrosine Kinase Inhibitor (TKI) Therapies

Hospitalizations of Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib: Results From a Randomized Phase III Trial

A Global Retrospective and Physician-Based Analysis of Adherence to Tyrosine Kinase Inhibitor (TKI) Therapies for Chronic Myeloid Leukemia (CML).

Number Needed to Treat (NNT) and Cost Estimation to Achieve a Major Molecular Response In Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia In Brazil

Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only